Skip to main content

Table 2 Demographic data and baseline characteristics (randomised set)

From: Evaluation of non-inferiority of intradermal versus adjuvanted seasonal influenza vaccine using two serological techniques: a randomised comparative study

  Total Intradermal vaccine Adjuvanted vaccine
  N = 795 N = 398 N = 397
Mean age (years; SD) 74.3 (6.4) 73.9 (6.3) 74.7 (6.6)
   - over 75 (n; %) 329 (41.4) 154 (38.7) 175 (44.1)
Males (n; %) 370 (46.5) 194 (48.7) 176 (44.3)
Mean body mass index (kg/m2; SD) 27.1 (4.5) 27.0 (4.5) 27.2 (4.5)
Past or current significant medical history (n; %) 715 (89.9) 358 (89.9) 357 (89.9)
   - risk factor a (n; %) 419 (52.7) 216 (54.3) 203 (51.1)
   - history of allergy b (n; %) 67 (8.4) 29 (7.3) 38 (9.6)
Last influenza vaccination c    
   - previous season 2006-2007 (n; %) 576 (72.5) 287 (72.1) 289 (72.8)
   - prior to previous season (n; %) 57 (7.2) 26 (6.5) 31 (7.8)
  1. Percentages are based on the number of randomised subjects having available data
  2. a At least one of the following: lung disease, heart disease, diabetes, renal disease, neurological abnormality or other significant medical history such as HIV, cancer, hepatitis (A, B, C), epilepsy, auto-immune diseases or blood disorders reported during the medical history review
  3. b At least one allergic condition reported as medical history
  4. c Percentages are calculated based on the number of randomised subjects who had previously been vaccinated against influenza and who had available data. 7 subjects (4 from the intradermal vaccine group and 3 from the adjuvanted vaccine group) had previously been vaccinated against influenza by the intradermal route